Director/PDMR Shareholding

RNS Number : 8624D
AstraZeneca PLC
29 March 2011
 



Transactions by Persons Discharging Managerial Responsibilities

Disclosure Rule DTR 3.1.4

 

On 28 March 2011, the following individuals, who are all persons discharging managerial responsibilities, were each granted awards under the terms of the AstraZeneca Investment Plan (AZIP) and the AstraZeneca Performance Share Plan (AZPSP) over the Company's ordinary shares, or, in the case of David Smith, Lynn Tetrault and Tony Zook, over the Company's American Depositary Shares (ADSs).  One ADS equals one ordinary share. 

 

 

Name

Shares awarded under AZIP

Shares awarded under AZPSP

Award price per share

 

Anders Ekblom

 

5,134

 

30,806

 

2853p

 

Martin Mackay

 

16,482

 

98,895

 

2853p

 

Mene Pangalos

 

6,554

 

39,327

 

2853p

 

Jeff Pott

 

8,824

 

52,944

 

2853p

 

David Smith

 

4,381

 

26,289

 

$46.18

 

Lynn Tetrault

 

6,714

 

40,285

 

$46.18

 

Tony Zook

 

16,178

 

97,069

 

$46.18

 

The AZIP was approved by shareholders at the Company's AGM in 2010.  These AZIP awards are subject to a four-year performance period and a subsequent four-year holding period.

 

The performance hurdle that applies to these AZIP awards relates to dividends and dividend cover. A summary of the AZIP can be found in the AstraZeneca Annual Report and Form 20-F Information 2010 which is available on the Company's website www.astrazeneca.com.

 

The AZPSP was approved by shareholders at the Company's AGM in 2005.  Awards made under the AZPSP may not generally vest before the third anniversary of the relevant date of grant, nor unless the specified performance target(s) have been met at the end of the three-year performance period which, for these awards, is 1 January 2011 to 31 December 2013.

 

The performance target that applies to these AZPSP awards relates to relative total shareholder return and cash flow.  A summary of the AZPSP can be found in the AstraZeneca Annual Report and Form 20-F Information 2010 which is available on the Company's website www.astrazeneca.com.

 

 

A C N Kemp

Company Secretary

29 March 2011

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSUKONRAOAOUAR

Companies

AstraZeneca (AZN)
UK 100

Latest directors dealings